Corcept Therapeutics CORT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's accounts receivable?
- Corcept Therapeutics (CORT) reported accounts receivable of $39.07M in Q1 2026.
- How has Corcept Therapeutics's accounts receivable changed year-over-year?
- Corcept Therapeutics's accounts receivable decreased by 36.8% year-over-year, from $61.82M to $39.07M.
- What is the long-term trend for Corcept Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accounts receivable has grown at a 17.9% compound annual growth rate (CAGR), from $26.2M to $59.79M.
- What does accounts receivable mean?
- The amount of money customers owe the company for goods or services already provided, minus estimated uncollectible amounts.
- How do you interpret accounts receivable?
- A rising balance relative to revenue may signal collection delays or credit risk, while a stable balance indicates efficient cash conversion.
- How does accounts receivable compare across companies?
- Pharmaceutical companies generally have predictable receivables based on distributor payment terms.